Dr. Barahimi is an assistant professor of medicine at the University of Washington with expertise in inflammatory bowel disease. She earned her bachelor’s degree and MD at the University of Washington. She went on to complete her residency in internal medicine and fellowship in gastroenterology at the University of Washington. In her clinical practice, she exclusively cares for patients with Crohn’s disease and ulcerative colitis. She is the principal investigator of IBD QORUS, a national quality improvement project that aims to improve the quality of care for patients with inflammatory bowel disease. She is also involved in clinical trials for new investigational therapies for inflammatory bowel disease. She is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy.
Mark Osterman, MD, MSCE is an Associate Professor of Medicine at the University of Pennsylvania Perelman School of Medicine where he serves as the Associate Director of IBD Research for the Penn Inflammatory Bowel Disease Center. He has been heavily involved in clinical research in inflammatory bowel disease for the last 10 years, with a focus on clinical trials of novel therapies, optimization and safety of medical therapies using observational studies, therapeutic drug monitoring of immunosuppressant medications, and mucosal healing.
He has been lead PI or a steering committee member of a number of multi-center clinical trials. He is one of the nation’s pioneers of the study and use of proactive therapeutic drug monitoring for biologic therapy in IBD. His work has been funded by the AGA, NIH, CCFA, pharmaceutical industries, and private philanthropy. Dr. Osterman has recently served as Chair of the Chapter Medical Advisory Committee for the CCFA Philadelphia Chapter, for which he is also a board member.
The inflammatory bowel disease (IBD) course is highly heterogenous. Intestinal fibrosis causing clinically apparent stricture formation is a common feature of both entities of IBD, Crohn’s disease and Ulcerative colitis and leads to a significantly impaired quality of life in affected patients, intestinal obstruction as well as need for surgical intervention. This constitutes a major treatment challenge, suppression of inflammation and the emergence of stronger immunosuppressive medications can only minimally reduce the incidence and prevalence of fibrostenosing IBD and no specific anti-fibrotic therapy is available.
Fibrosis results from the response of gut tissue to the insult inflicted by chronic inflammation. The underlying fibrogenic mechanisms are complex and dynamic, involving multiple cell types, interrelated cellular events, and a large number of soluble factors. These features are shared across organs, such as liver, skin, kidney or heart. Owing to a breakdown of the epithelial barrier in IBD, luminal bacterial products leak into the interstitium and induce an innate immune response mediated by activation of both immune and non-immune cells. Damage-associated molecular patterns, intracellular components released by necrotic cells, can also induce mesenchymal cell activation and contribute to stricture formation. Fat wrapping around the bowel wall, the so-called ‘creeping fat’, typical of Crohn’s disease, can drive fibrogenesis through the release of free fatty acids that induce intestinal muscle cell proliferation. Clinical and experimental evidence indicates that once fibrosis is established it can progress independently of inflammation. The composition of the intestinal extracellular matrix, its mechanoproperties and matrix bound factors are dramatically altered in chronic gut inflammation and can actively promote fibrosis. Identification of the unique mechanisms of intestinal fibrogenesis should create a practical framework to target and blockade specific fibrogenic pathways.
Our group focusses on the discovery of novel mechanisms of intestinal fibrogenesis, the prediction of fibrostenosing disease courses and innovative ways to treat IBD patients with established strictures. For this purpose, we are using primary human cells, tissues and organ culture systems as well as novel animal models of intestinal fibrosis. We have established an IBD biomarker cohort and assess endoscopic techniques to treat fibrostenosing IBD.
Teresa Wachs is a registered nurse at Seattle Children’s in the IBD Center. She attended Iowa Methodist School of Nursing and Drake University. She is certified in ambulatory care and Case Management. Teresa is a member of the Crohn’s and Colitis Medical Advisory Committ.ee and co-medical director of IBD Camp Oasis.
Dr. Glenn M Koteen, MD is a Doctor primarily located in Bend, OR, with another office in Bend, OR. He has 40 years of experience. His specialties include Gastroenterology and Internal Medicine
Patients’ Choice Award (2018)
Patients’ Choice recognition reflects the difference a particular physician has made in the lives of his/her patients. The honor is bestowed to physicians who have received near perfect scores, as voted by patients
Compassionate Doctor Recognition (2018)
Compassionate Doctor certification is granted to physicians who treat their patients with the utmost kindness. The honor is granted based on a physician’s overall and bedside manner scores.
Dr. Kinnucan received her bachelor’s degree from the University of Wisconsin-Madison. She studied medicine at the University of Chicago Pritzker’s School of Medicine. She then went on to complete her training in internal medicine training at Northwestern University and completed her gastroenterology and inflammatory bowel disease (IBD) training at the University of Chicago with Drs. David Rubin and Stephen Hanauer. Dr. Kinnucan’s clinical focus is in the treatment of patients with IBD, which includes Crohn’s disease and ulcerative colitis. She is particularly interested in how sleep quality affects IBD patient’s disease activity and quality of life, the effects of inflammation on the development of colorectal cancer in patients with IBD, and the management of IBD during pregnancy and lactation. Dr. Kinnucan serves on the Patient Education Committee for the Crohn’s and Colitis Foundation of America.
Kindra is a board certified nurse practitioner with a clinical focus on inflammatory bowel disease. She earned her bachelor’s degree in biology at Willamette University and completed her bachelor’s in nursing and Doctor of Nursing Practice at the University of Washington, School of Nursing. Kindra works as a nurse practitioner in the University of Washington, Digestive Health Center, Inflammatory Bowel Disease Clinic, caring for patients with Crohn’s disease and Ulcerative colitis. She also works as an investigator on the University of Washington, Inflammatory Bowel Disease Research Program, assisting with clinical trials and investigator initiated studies.
Dr. Hussain is a clinical pharmacist at the University of Washington (UW) Medical Center in the Digestive Health Center and Hepatology Clinics and Clinical Instructor with the UW School of Pharmacy. Dr. Hussain earned her Bachelor’s degree in biology at George Mason University and Doctor of Pharmacy degree at Hampton University. She then completed a 1-year post-graduate residency in pharmacy practice at Georgetown University. Currently, she works as a clinical pharmacist with providers, nurses, MAs, and clinic team to manage patients with inflammatory bowel disease (Crohn’s disease and Ulcerative Colitis) and Hepatitis C. She is a member of the Crohn’s and Colitis Foundation.
Dr. Chiorean is the director of the IBD Center of Excellence at Virginia Mason, director of Digestive Disease Institute Research, is a fellow of the American Gastroenterology Association and a board member of the Crohn’s and Colitis Foundation of America, where he serves on the Patient Education Committee.
Dr. Chiorean’s medical interests include inflammatory bowel disease, Crohn’s disease, ulcerative colitis, C Difficile, gastrointestinal bleeding and small bowel endoscopy.
Dr. Harper is the director of the Harborview Medical Center Inflammatory Bowel Disease program, and is a UW clinical assistant professor. He earned his M.D. from Columbia University, and did his internal medicine and gastroenterology training at the University of Washington. He is a member of the Crohn’s and Colitis Foundation, and is presently on the regional Medical Advisory Committee.
Dr. Harper’s clinical interests include inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) His research interests include clinical outcomes in IBD